New drug cocktail aims to wipe out breast cancer before surgery
NCT ID NCT07396324
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding an immunotherapy drug called QL1706 to standard chemotherapy before surgery can improve outcomes for people with HR-positive, HER2-negative breast cancer. About 55 participants will receive the combination, and researchers will measure how many have no cancer cells left at the time of surgery. The trial is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and Tuvonralimab (QL1706) plus chemotherapy (paclitaxel and carboplatin)
- What this could lead to
- If successful, this could lead to a more effective pre-surgery treatment for HR+/HER2- breast cancer, potentially increasing the chance of no cancer remaining at surgery.
- What could go wrong
- This is an early Phase 2 trial with only 55 participants and no control group, so results may not be conclusive. The combination may cause significant side effects from chemotherapy and immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITINGShanghai, 200127, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- New hope for breast cancer patients: experimental drug combo enters Mid-Stage trial
- Could a simple hormone test spare thousands of women from chemo?
- New radiation 'Smart Bomb' targets Hard-to-Treat cancers in early trial
- New pill combo aims to keep breast cancer from returning
- New cancer pill HLX97 enters first human tests